Latest Bella A. Peyronie Stories
CHESTERBROOK, Pa., Feb. 1, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that The Journal of Urology has electronically published the uncorrected proof of the Company's pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, in-office, biologic for the...
MALVERN, Pa., Nov. 7, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD). XIAFLEX for the treatment of PD was granted orphan...
MALVERN, Pa., Aug. 27, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX® (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD)....
MALVERN, Pa., June 4, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD)....
MALVERN, Pa., May 9, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that The Journal of Urology has published on its website, the Company's phase IIb clinical trial of XIAFLEX® (collagenase clostridium histolyticum or CCH) a novel, first-in-class, biologic for the potential nonsurgical treatment of Peyronie's disease. Top line data from this trial has been previously reported by the Company. The study...
MALVERN, Pa., March 22, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) and Asahi Kasei Pharma Corporation announced today that they have entered into a long-term strategic alliance for the development, commercialization and supply of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the treatment of Dupuytren's contracture and Peyronie's disease. Under the terms of the agreement, Asahi Kasei Pharma will receive exclusive rights to...
MALVERN, Pa., March 9, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX(® )for the treatment of Peyronie's disease. In accordance with the study design, all enrolled patients will have received their first injection of either XIAFLEX or placebo by the end of March 2011. The Company will exceed its enrollment...
MALVERN, Pa., Feb. 10, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the fourth quarter and the year ended December 31, 2010. The Company also highlighted important commercial, regulatory and clinical development progress during the year 2010 and provided financial and operational guidance for 2011. (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) For the quarter ended December...
MALVERN, Pa., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2010. For the third quarter of 2010, Auxilium reported net revenues of $53.6 million compared to net revenues of $42.1 million in the third quarter of 2009. The net loss for the third quarter of 2010 was $(12.8) million, or $(0.27) per share, compared to a...
